Abstract:Rationale The emerging evidence suggested that senescence regulator genes were involved in multi cancers, which may be utilized as new targets for cancers. However, the dysregulation and clinical impact of senescence regulator genes in clear cell renal cell cancer (ccRCC) were still in foggy. Methods Using multi-omics data from TCGA-KIRC and other datasets, we comprehensively investigated the function of senescence regulator genes in ccRCC. ccRCC patients could be remodeled into two significant different groups basing on senescence regulators expression: senescence-pattern cancer subtype1 (SPCS1) and subtype2 (SPCS2). We further explored clinical characteristics, functional analysis, tumor immune microenvironment, immunotherapy response, genomic mutation and drug sensitivity between the two subtypes. Besides, senescence-pattern related risk model was established to determine the patient's prognosis of ccRCC. Finally, the overview of MECP2 function was investigated in multi cancers. Results ccRCC patients could be divided into SPCS1 (normal aging group) and SPCS2 (Aging disorder group). The two subtypes showed significant different clinical characteristics and biological process in ccRCC. SPCS2, an aggressive subtype, comprised higher clinical stage and worse prognosis of ccRCC patients. SPCS2 subtype indicated activated oncogenic signaling pathway and metabolic signatures to prompt cancer expansion. SPCS2 subgroup owned immunocompromised status, which induced immune dysfunction and low ICI therapy response. The genome-copy numbers of SPCS2, including arm-gain and arm-loss was significantly more frequent than SPCS1. In addition, the two subtypes argue contrasting drug sensitivity profiles in clinical specimens and matched cell lines. Finally, we constructed a prognostic risk model consisted of each subtype's leading biomarkers, which exerted a satisfied performance for ccRCC patients. Conclusion Senescence regulator-related signature could modify functional pathways and tumor immune microenvironment by genome mutation and pathway interaction. Senescence regulator-related molecular subtype strengthen the understanding of ccRCC' characterization and guide clinical treatment. Targeting senescence regulators may be regard as a proper way in ccRCC. Micro- The emerging evidence suggested that senescence regulator genes might involve in the progression of clear cell renal cell cancer, while the details remain larger unknown. In this work, we comprehensively investigated the function of senescence regulator genes in ccRCC across multi omics and validated the findings with experiments. ccRCC patients could be divided into SPCS1 (normal aging group) and SPCS2 (Aging disorder group). SPCS2, an aggressive subtype, comprised higher clinical stage and worse prognosis, which indicated activated oncogenic signaling pathway and metabolic signatures to prompt cancer expansion. SPCS2 subgroup owned immunocompromised status, which induced immune dysfunction and low ICI therapy response. In conclusion, senescence regulator-related signature could modify functional pathways and tumor immune microenvironment by genome mutation and pathway interaction.

Spindle Pole Body Component 24 Homolog Potentiates Tumor Progression Via Regulation of SRY-box Transcription Factor 2 in Clear Cell Renal Cell Carcinoma.

SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma

Upregulation of Serine Metabolism Enzyme PSAT1 Predicts Poor Prognosis and Promotes Proliferation, Metastasis and Drug Resistance of Clear Cell Renal Cell Carcinoma.

Bioinformatics Analysis of Prognostic Value of <i>SPC24</i> in ccRCC and Pan-Cancer

SPC24 Regulates breast cancer progression by PI3K/AKT signaling.

SPC24 Regulates Breast Cancer Progression by PI3K/AKT Signaling

KLF2-induced circZKSCAN1 potentiates the tumorigenic properties of clear cell renal cell carcinoma by targeting the miR-1294/PIM1 axis

Interferon Regulatory Factor 2 (IRF2) Inhibits the Invasion and Migration of Renal Clear Cell Carcinoma Cells by Downregulation of Spindle Pole Body Component 24 (SPC24)

An In Silico Investigation of SPC24 as a Putative Biomarker of Kidney Renal Clear Cell Carcinoma and Kidney Renal Papillary Cell Carcinoma for Predicting Prognosis and/or Immune Infiltration

CircSP3 encodes SP3-461aa to promote ccRCC progression via stabilizing MYH9 and activating the PI3K-Akt signaling pathway

SPCS, a novel classifier system based on senescence axis regulators reveals tumor microenvironment heterogeneity and guides frontline therapy for clear cell renal carcinoma

SPC25 upregulates CCND1 to promote the progression of esophageal squamous cell carcinoma by MDM2-mediated E2F1 ubiquitination and stabilization

Spindle component 25 predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis

SPOP Promotes Tumor Progression Via Activation of Β-Catenin/tcf4 Complex in Clear Cell Renal Cell Carcinoma.

Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma

A Novel Prognostic Biomarker SPC24 Up-Regulated in Hepatocellular Carcinoma

Up-regulation of SLC27A2 Suppresses the Proliferation and Invasion of Renal Cancer by Down-Regulating CDK3-mediated EMT

Downregulation of Ubiquitin-Specific Protease 2 Possesses Prognostic and Diagnostic Value and Promotes the Clear Cell Renal Cell Carcinoma Progression

SPC25 Promotes Proliferation and Stemness of Hepatocellular Carcinoma Cells Via the DNA-PK/AKT/Notch1 Signaling Pathway

Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma

Mutant CDKN2A regulates P16/p14 expression by alternative splicing in renal cell carcinoma metastasis